Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Carcinoma 4Squamous Cell Carcinoma of Head and Neck 3Mouth Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Adenocarcinoma 3Recurrence 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Laryngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1Skin Neoplasms 1Sinonasal Squamous Cell Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Liposarcoma 1Hemangiosarcoma 1

Interventions

Cyclophosphamide 9fludarabine 7Dexamethasone 7pomalidomide 6Rituximab 6pembrolizumab 5selinexor 4obinutuzumab 4glofitamab 4Lenalidomide 4daratumumab 3belantamab mafodotin 3Temozolomide 3Gemcitabine 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2fludarabine phosphate 2enzalutamide 2cemiplimab 2carfilzomib 2abemaciclib 2PF06821497 2Mesna 2Lisaftoclax 2Injections 2Immunotherapy, Adoptive 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × cemiplimab × 30 days × Clear all
NCT06769698 2026-05-06

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 2 Recruiting
120 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT07567469 2026-05-05

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
120 enrolled
CNS

Ependymoma, Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡